Caricamento...
The pharmacokinetics and safety of darapladib in subjects with severe renal impairment
AIM: Darapladib is a potent and reversible orally active inhibitor of lipoprotein-associated phospholipase A(2) (Lp-PLA(2)). The aim of the study was to assess the effects of severe renal impairment on the pharmacokinetics and safety/tolerability of darapladib compared with normal renal function. ME...
Salvato in:
| Pubblicato in: | Br J Clin Pharmacol |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley & Sons, Ltd
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4594701/ https://ncbi.nlm.nih.gov/pubmed/25953363 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12661 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|